FDA-cleared second and third trimester preeclampsia test developed by ThermoFisher looks at risks from hypertension to severe features of preeclampsia 

The blood test, with a turnaround time of 1-2 days, is designed for hospitalized patients between 23-35 weeks of gestation and works by analyzing the ratio of biochemical markers, with a ratio number of 40 or more indicating high risk for preeclampsia and under 40 indicating low risk. This test is not a standalone test and should be used as an additional tool to assess a patient’s risk with its performance characteristics based on the PRAECIS study. 

The District of Columbia Perinatal Quality Collaborative Grant is managed by the District of Columbia Hospital Association Program Services Company, Inc.

This DC Perinatal Quality Collaborative Grant Program is funded wholly or in part by the Government of the District of Columbia Department of Health.